Regulação e direito · 30/12/20051 min de leitura
Prospective Grant of Exclusive License: Fusion Proteins Comprising Circularly Permuted Ligands
Tradução automática local · Idioma original da fonte
Resumo
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in United States Patent No. 4,892,827, issued on January 9, 1990, entitled "Recombinant Pseudomonas Exotoxin: Construction Of An Active Immunotoxin With Low Side Effects" [E-385-1986/0-US-01]; U.S. Patent No. 5,635,599, issued on June 3, 1997, entitled "Fusion Proteins Comprising Circularly Permuted Ligands" [E-047-1994/0-US-01]; PCT Patent Application No. PCT/US95/04468, filed April 6, 1995, entitled "Fusion Proteins Comprising Circularly Permuted Ligands" [E-047-1994/ 0-PCT-02]; Switzerland Patent No. 0754192, issued on January 29, 2003, entitled "Fusion Proteins Comprising Circularly Permuted Ligands" [E- 047-1994/0-CH-03]; Spain Patent No. 0754192, issued on January 29, 2003, entitled "Fusion Proteins Comprising Circularly Permuted Ligands" [E-047-1994/0-ES-04]; United Kingdom Patent No. 0754192, issued on January 29, 2003, entitled "Fusion Proteins Comprising Circularly Permuted Ligands" [E-047-1994/0-GB-05]; Italy Patent No